Pharmaceutical Technology

DECEMBER 16, 2022

This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. of 7MM sales. GlobalData’s report also covers a third pipeline candidate, quinagolide, a dopamine receptor antagonist being developed by Ferring Pharmaceuticals.

Marketing 59

Marketing Side effects Sales Safety 59

pharmaphorum

JANUARY 9, 2023

Albireo secured approval in the US and Europe for the ileal bile acid transport inhibitor (IBATi) drug in 2021 for the treatment of pruritus (itching) in patients with rare disorder progressive familial intrahepatic cholestasis (PFIC), and has said sales should reach $24 million this year. billion deal.

Transportation 52

Transportation Sales Leads FDA 52

pharmaphorum

SEPTEMBER 22, 2022

The company said this morning that US sales growth is its main priority, and that it will be led in the near-term by “high-value” new drugs Kisqali (ribociclib), iptacopan, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), remibrutinib, and Scemblix (asciminib). billion by 2024.

Management 52

Management Sales Patients Marketing 52

pharmaphorum

OCTOBER 6, 2022

Lilly already has approval for the dual GLP-1/GIP agonist under the Mounjaro brand name as a diabetes therapy and is tipped to make rapid inroads in that market, with EvaluatePharma predicting sales could break the $1 billion barrier in 2024, and $3 billion two years later. billion in 2025 sales.

Sales 52

Sales Marketing FDA Leads 52

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. Top companies and drugs by sales in 2021. 2022;21(4):251–.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

PM360

JULY 13, 2023

The future of healthcare is undoubtedly digital, and those who embrace this reality will certainly lead the way. MarketsandMarkets, “Polyols Market by Type, Application, End-use Industry, and Region – Global Forecast to 2027,” December 2022. References: 1.

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

Pharmaceutical Technology

NOVEMBER 30, 2022

Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Bariatric surgeries show 30% weight loss in the first year and 25% weight loss in the long term,” says Papamargaritis, while that the clinical data for Mounjaro shows that the drug leads to a 16–22.5%

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

JANUARY 10, 2023

billion in sales in 2019, increasing to $136.2 billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Mounjaro is forecast to compete for significant market share with semaglutide and also Lilly’s Trulicity (dulaglutide), reaching peak sales of $10.2

Marketing 52

Marketing Physicians Sales Leads 52

Pharmaceutical Technology

NOVEMBER 30, 2022

Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Bariatric surgeries show 30% weight loss in the first year and 25% weight loss in the long term,” says Papamargaritis, while that the clinical data for Mounjaro shows that the drug leads to a 16–22.5%

Medical 98

Medical Manufacturing Insurance Side effects 98

PM360

APRIL 7, 2023

Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.”

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Clarivate

JULY 16, 2019

Here are some CX statistics that we have gathered and should get the attention of your CEO and CFO, and lead to further CX progress for your company. . By 2027, 75% percent of today’s S&P 500 companies will be replaced by new companies which are providing the best customer experience to their customers.

Competition 40

Competition Sales Leads Marketing 40

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

World of DTC Marketing

JUNE 4, 2021

Mike always battled weight issues, but since he went out on disability, he had gained more weight, leading to diabetes. An unhealthy diet is one of the leading risk factors for poor health and accounts for up to 45% of all deaths from these cardiometabolic diseases, the researchers noted. That’s about $375 per month.

Food 207

Food Insurance Leads Medical 207

PM360

JUNE 29, 2022

By 2025, sales of consumer health products are expected to reach $368bn, according to Euromonitor, encompassing everything from sleep aids to vitamins to sports nutrition products. markets by 2025 and 1,000 by 2027—and more than half of those practices are expected to be in medically underserved communities.

Retail 97

Retail Marketing Healthcare Healthcare 97

Medico Reach

FEBRUARY 8, 2023

AI can lead to faster research, combining and extracting data into usable formats, making clinical trials more efficient and saving time. Pharma companies can utilize big data to predict the sale of a particular medicine owing to various demographic factors. billion by 2027.

Pharma 52

Pharma Medicine Marketing Prospecting 52

PM360

SEPTEMBER 21, 2023

GoodRx is the leading platform 2 with the highest unaided awareness and trust across patients, physicians, and pharmacists 3 that Americans—regardless of insurance status—use across many phases of their healthcare journey. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.

Prescription 52

Prescription Medical Patients Distribution 52

Pharmaceutical Technology

APRIL 24, 2023

The rise of biologics In the lead-up to the 2020 boom, Swiss drugmaker Roche spent some $11 billion on biotechnology research and development in 2018. Syngene, which is among the leading CRDMOs in India, has biologics facilities that can produce a large array of products across mammalian and microbial platforms.

Manufacturing 52

Manufacturing Food and Drug Administration Biopharma Sales 52

Star OUTiCO

FEBRUARY 18, 2022

The European Union’s EU4Health 2021-2027 budget, for example, allocates €5.3 When it comes to future-proofing new and existing sales teams by equipping them with the tools to succeed in virtual selling, our Digital In-Call Excellence (DICE), programme trumps anything else out there.

Pharma 52

Pharma Healthcare Healthcare Patients 52